RankingsPricing
  1. US-listed companies
  2. CAPRICOR THERAPEUTICS, INC.
  3. Raw

CAPRICOR THERAPEUTICS, INC.CAPR

Market cap
$1.2B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-----------20,022,520-29,019,532-22,287,542-40,467,186
Loss on disposal of fixed assets-1,501--------2,720--7,905-34,266-6,041-112,805
Depreciation and amortization320,648326,904164,73241,896110,865125,719144,174157,652171,956143,890245,697533,13111
Stock-based compensation1011666,123496,9392222700,984234710
Noncash Lease Expenses----------129,726161,740-24,282-47,261
Receivables---360,233-148,29511,397121,240-139,707-116,900-87,968391,750155,83010-3,504
Prepaid expenses and other assets271,298124,912----------240,04575,884458,653
Accounts payable and accrued expenses--170,329831,246508,280-1,542,073-347,398-273,1752400,750212
Deferred revenue-----------27-3,178,066-12,270,465
Net cash used in operating activities-4,649,292-2,186,681-----14,230,879-13,862,441-6,821,501-10,054,810-16,809,3245-25,596,545-39,995,742
Purchase of marketable securities--4-1818191866-11497208
Proceeds from Sale and Maturity of Marketable Securities--4327,47410132423312-8310594
Purchases of property and equipment130,855130,855284,923186,431129,697191,97032,185316,486-547,6011211
Payments for leasehold improvements-----------1735,873372,104
Net cash provided by (used in) investing activities-1,987-----55-3,002,0505-1,196,286-35,072,5075-116,183,868
Net proceeds from sale of common stock5,0005,000--161411792720526152
Proceeds from Stock Options And Warrant Exercises-------------450,173
Net cash provided by financing activities3435----12793320526153
Net increase (decrease) in cash and cash equivalents------2-2,337,040-645,769292-25,282,0325-3,407,861
Interest Paid, Net--------------
Income Taxes Paid, Net--------------